215 related articles for article (PubMed ID: 30858637)
1. Paroxetine
Callegari C; Ielmini M; Caselli I; Lucca G; Isella C; Diurni M; Pettenon F; Poloni N
Psychopharmacol Bull; 2019 Feb; 49(1):28-43. PubMed ID: 30858637
[TBL] [Abstract][Full Text] [Related]
2. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
Baune BT; Sluth LB; Olsen CK
J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
[TBL] [Abstract][Full Text] [Related]
3. Vortioxetine improves physical and cognitive symptoms in patients with post-COVID-19 major depressive episodes.
Di Nicola M; Pepe M; Montanari S; Spera MC; Panaccione I; Simonetti A; Sani G
Eur Neuropsychopharmacol; 2023 May; 70():21-28. PubMed ID: 36808043
[TBL] [Abstract][Full Text] [Related]
4. Effect of vortioxetine in subjects with major depressive and alcohol use disorders: a 6-month retrospective analysis.
Di Nicola M; Pepe M; Panaccione I; Moccia L; Dattoli L; Molinaro M; Sani G; Janiri L; McIntyre RS
CNS Spectr; 2022 Feb; 27(1):73-81. PubMed ID: 32772956
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
[TBL] [Abstract][Full Text] [Related]
6. Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial.
Jacobsen P; Zhong W; Nomikos G; Clayton A
J Sex Med; 2019 Oct; 16(10):1638-1649. PubMed ID: 31405765
[TBL] [Abstract][Full Text] [Related]
7. Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years.
Barrett JE; Williams JW; Oxman TE; Frank E; Katon W; Sullivan M; Hegel MT; Cornell JE; Sengupta AS
J Fam Pract; 2001 May; 50(5):405-12. PubMed ID: 11350703
[TBL] [Abstract][Full Text] [Related]
8. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.
Kornstein SG; Clayton AH; Bao W; Guico-Pabia CJ
J Womens Health (Larchmt); 2015 Apr; 24(4):281-90. PubMed ID: 25860107
[TBL] [Abstract][Full Text] [Related]
9. Results of a real-world study on vortioxetine in patients with major depressive disorder in South East Asia (REVIDA).
Chin CN; Zain A; Hemrungrojn S; Ung EK; Kwansanit P; Au Yong KC; Chong MSW; Inpa C; Yen TH; Yeoh BBD; Tay LK; Bernardo C; Lim LC; Yap CH; Fones C; Nayak A; Nelleman L
Curr Med Res Opin; 2018 Nov; 34(11):1975-1984. PubMed ID: 29768955
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms.
Soares CN; Poitras JR; Prouty J; Alexander AB; Shifren JL; Cohen LS
J Clin Psychiatry; 2003 Apr; 64(4):473-9. PubMed ID: 12716252
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).
McElroy SL; Weisler RH; Chang W; Olausson B; Paulsson B; Brecher M; Agambaram V; Merideth C; Nordenhem A; Young AH;
J Clin Psychiatry; 2010 Feb; 71(2):163-74. PubMed ID: 20122366
[TBL] [Abstract][Full Text] [Related]
12. Real-world clinical outcomes and treatment patterns in patients with MDD treated with vortioxetine: a retrospective study.
McDaniel BT; Cornet V; Carroll J; Chrones L; Chudzik J; Cochran J; Guha S; Lawrence DF; McCue M; Sarkey S; Lorenz B; Fawver J
BMC Psychiatry; 2023 Dec; 23(1):938. PubMed ID: 38093196
[TBL] [Abstract][Full Text] [Related]
13. Mirtazapine compared with paroxetine in major depression.
Benkert O; Szegedi A; Kohnen R
J Clin Psychiatry; 2000 Sep; 61(9):656-63. PubMed ID: 11030486
[TBL] [Abstract][Full Text] [Related]
14. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of vortioxetine on the physical symptoms of major depressive disorder.
Christensen MC; Florea I; Lindsten A; Baldwin DS
J Psychopharmacol; 2018 Oct; 32(10):1086-1097. PubMed ID: 30047820
[TBL] [Abstract][Full Text] [Related]
16. Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease.
Moonen AJ; Wijers A; Leentjens AF; Christine CW; Factor SA; Juncos J; Lyness JM; Marsh L; Panisset M; Pfeiffer R; Rottenberg D; Serrano Ramos C; Shulman L; Singer C; Slevin J; McDonald W; Auinger P; Richard IH
Parkinsonism Relat Disord; 2014 Jun; 20(6):644-6. PubMed ID: 24679737
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Tolerability of Two Different Kinds of Titration of Paroxetine Hydrocloride Solution: an Observational Study.
Ielmini M; Poloni N; Caselli I; Bianchi L; Diurni M; Vender S; Callegari C
Psychopharmacol Bull; 2018 Mar; 48(3):33-41. PubMed ID: 29713104
[TBL] [Abstract][Full Text] [Related]
18. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder.
Wang G; Zhao K; Reynaud-Mougin C; Loft H; Ren H; Eriksen HF; Ettrup A
Curr Med Res Opin; 2020 May; 36(5):875-882. PubMed ID: 31990207
[No Abstract] [Full Text] [Related]
19. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram.
Levada OA; Troyan AS
J Affect Disord; 2019 May; 250():114-122. PubMed ID: 30852363
[TBL] [Abstract][Full Text] [Related]
20. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
Mouchabac S; Ferreri M; Cabanac F; Bitton M
Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
